Renal Cancer
Iceball Margin < 5 mm Is Associated with Local Failure after CT-Guided Cryoablation of cT1a Renal Cell Carcinoma - Beyond the Abstract
- Details
Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications.
- Details
Neoadjuvant systemic therapy for clear cell renal cell carcinoma (ccRCC) aim to improve oncological and survival outcomes in patients with high-risk disease. This review evaluates contemporary evidence for neoadjuvant and perioperative systemic therapies in ccRCC, with a focus on localised high-risk disease, venous tumour thrombus and metastatic or cytoreductive settings.
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
- Details
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare, molecularly defined subgroup of non-clear cell RCC (nccRCC) lacking an approved standard treatment. We report the exploratory analysis of this entity within the SUNNIFORECAST trial.
The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study.
- Details
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30-40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC.
A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.
- Details
Clear cell renal cell carcinoma (ccRCC) is the most common, aggressive renal malignancy with a poor prognosis and limited advanced therapies.Accumulating evidence highlights the importance of sialylation and sialylation-related long non-coding RNAs (lncRNAs) in tumor progression, immune evasion, and treatment resistance.
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.
- Details
Background/Objectives: Nivolumab monotherapy is a standard of care in previously treated advanced renal cell carcinoma (aRCC) and was approved based on the results of the randomized clinical trial Checkmate-025.
Risk Stratification in Renal Cell Carcinoma: A Narrative Review.
- Details
Renal cell carcinoma (RCC) accounts for the majority of kidney cancers, with approximately 80,000 new diagnoses and over 14,000 deaths annually in the United States. Risk stratification is essential for prognostication, treatment selection, and clinical trial design across all disease stages.
Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.
- Details
Discordant responses to immune checkpoint inhibition (ICIs) may occur at different sites in metastatic renal cell carcinoma (mRCC). This study investigated the incidence and prognostic significance of mixed response in mRCC patients treated with nivolumab.
Integrative analysis prioritizes proteins associated with renal cell carcinoma and its risk factors.
- Details
Renal cell carcinoma (RCC), the predominant form of kidney cancer, is influenced by several risk factors (RFs) including obesity, hypertension, and smoking. However, the molecular mechanisms linking these RFs to RCC remain unclear.
First report of safety and outcomes of radiofrequency ablation of renal tumors using a new automated energy delivery-controlled system.
- Details
The aim of this study was to retrospectively evaluate technical efficacy and safety of radiofrequency ablation (RFA) of renal tumors using a novel RF system.
Eighty-two patients with 85 renal tumors (renal cell, papillary and chromophobe carcinomas, oncocytomas and lymphoma) considered unsuitable for surgery by the local Multidisciplinary Board were enrolled for RFA.